Details

Autor(en) / Beteiligte

• PETERMANN, W
• ALEGRE-MARTIN, J
• ODENHOLT, I
• PHILLIPS, M. J
• WILLCOX, P. A
• TACK, K
• TROSTMANN, U
• WELLING, L

Titel

A Prospective, Randomized, Multicenter Comparative Study of Clinafloxacin Versus a Ceftriaxone-based Regimen in the Treatment of Hospitalized Patients with Community-acquired Pneumonia

Ist Teil von

• Scandinavian journal of infectious diseases, 2001, Vol.33 (11), p.832-837

Ort / Verlag

Basingstoke: Informa UK Ltd

Erscheinungsjahr

2001

Quelle

Taylor & Francis

Beschreibungen/Notizen

• In an open-label, phase 3, randomized, multicenter study, clinafloxacin (200 mg/d) was compared to ceftriaxone (2 g/d; with or without erythromycin) in 527 patients with acute community-acquired bacterial pneumonia (CAP). Primary efficacy parameters were clinical cure rate and microbiologic eradication rates (by pathogen and by patient) determined 5?9 d post-therapy (test of cure; TOC). Clinical cure rates at TOC for the 2 treatment groups were equivalent in the intention-to-treat (clinafloxacin 79.3, ceftriaxone 78.6%), clinically evaluable (clinafloxacin 88.1, ceftriaxone 85.0%), modified intention-to-treat (clinafloxacin 82.6, ceftriaxone 86.9%) and microbiologically evaluable populations (clinafloxacin 86.2, ceftriaxone 86.2%). Microbiologic eradication rates were similar in the 2 treatment groups. Both drugs were tolerated. Treatment of hospitalized CAP patients with clinafloxacin is a reasonable choice, especially when a resistant pathogen is anticipated.